Oncopeptides

Oncopeptides Current Liabilities

The Current Liabilities of Oncopeptides (ONCO.ST) as of Nov 10, 2026 is 44.50 M SEK. In the previous year, Current Liabilities was 73.75 M SEK — a change of -39.65% (lower).

Current Liabilities

44.50 MSEK

YoY

-39.65%

Last updated:

Current Liabilities of Oncopeptides is 2025 44.50 M SEK. Current Liabilities of Oncopeptides was 2024 73.75 M SEK. It decreases by -39.65% lower compared to the previous year.

The Oncopeptides Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
137.70 M SEK
Jan 1, 2019
150.14 M SEK
Jan 1, 2020
291.14 M SEK
Jan 1, 2021
222.18 M SEK
Jan 1, 2022
103.68 M SEK
Jan 1, 2023
70.44 M SEK
Jan 1, 2024
73.75 M SEK
Jan 1, 2025
44.50 M SEK
The Oncopeptides Current Liabilities history
YEARCurrent LiabilitiesYoY
44.50 MSEK-39.65%
73.75 MSEK+4.69%
70.44 MSEK-32.06%
103.68 MSEK-53.33%
222.18 MSEK-23.69%
291.14 MSEK+93.91%
150.14 MSEK+9.04%
137.70 MSEK+108.34%
66.09 MSEK+69.70%
38.95 MSEK+357.29%
8.52 MSEK+6.60%
7.99 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oncopeptides Stock analysis

What does Oncopeptides do? Oncopeptides AB is a biopharmaceutical company specializing in the research and development of novel therapeutics for the treatment of cancer. The company was founded in 2000 in Uppsala, Sweden. Oncopeptides' research focuses on the discovery of substances that can affect specific cellular processes, inhibiting or even killing the growth of cancer cells. The company places particular emphasis on the development of drugs that can be targeted against specific types of cancer and have minimal side effects. The business model of Oncopeptides is based on licensing developed drugs to other companies or marketing their own products. This allows for faster progress in development and minimizes entrepreneurial risk. The company is divided into three different divisions, focusing on different types of cancer. The first division specializes in the treatment of multiple myeloma, the second in the treatment of solid tumors, and the third in the development of diagnostic tests for early cancer detection. The first product that Oncopeptides has brought to market is the drug Ygalo. It is used to treat patients with advanced multiple myeloma who do not respond to other therapies. Ygalo is a peptide mimetic specifically designed to inhibit the protein MCL-1, which plays a key role in cell proliferation in many types of cancer. In the second division of Oncopeptides, the company focuses on the development of drugs that can be specifically targeted against solid tumors such as lung, breast, or colorectal cancer. The protein BET inhibitor is targeted, which plays an important role in the regulation of gene expression in many types of cancer. The third division of Oncopeptides is engaged in the development of diagnostic tests that enable early detection of cancer. Both blood tests and imaging techniques are used to detect changes in the body that could indicate cancer. The focus is on the development of tests that can detect early signs of cancer, enabling timely diagnosis and treatment. Overall, Oncopeptides is a promising company specializing in the development of innovative therapeutics in cancer treatment. With its focus on specific cellular processes and targeted approaches to fighting different types of cancer, the company is on a promising path to bring more products to market that can improve the lives of many cancer patients. Oncopeptides is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncopeptides stock

Current Liabilities of Oncopeptides is 44.50 M SEK in 2025.

Current Liabilities of Oncopeptides changed from 73.75 M SEK to 44.50 M SEK, representing a -39.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Oncopeptides since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Oncopeptides historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Oncopeptides

All Key Metrics — Oncopeptides